Patents Assigned to Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.
-
Patent number: 11766447Abstract: The present disclosure relates to 3?3?-cyclic dinucleotides having a carbocyclic nucleotide and derivatives that can modulate the activity of the STING adaptor protein.Type: GrantFiled: March 4, 2020Date of Patent: September 26, 2023Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Gabriel Birkus, Petra Brehova, Milan Dejmek, Radim Nencka, Ondrej Pav, Michal Sala
-
Publication number: 20220160746Abstract: The present disclosure relates to 3?3?-cyclic dinucleotides having a carbocyclic nucleotide and derivatives that can modulate the activity of the STING adaptor protein.Type: ApplicationFiled: March 4, 2020Publication date: May 26, 2022Applicant: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.IInventors: Gabriel BIRKUS, Petra BREHOVA, Milan DEJMEK, Radim NENCKA, Ondrej PAV, Michal SALA
-
Publication number: 20220152078Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of Formula (I), the pharmaceutically acceptable salts, pharmaceutical composition and combinations of the substances and other medicaments or pharmaceuticals. The disclosure also relates to the compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases.Type: ApplicationFiled: March 4, 2020Publication date: May 19, 2022Applicant: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Gabriel BIRKUS, Ondrej PAV, Ondrej KOSTOV, Petra BREHOVA, Martin Maxmilian KAISER, Ondrej SIMAK
-
Publication number: 20220143061Abstract: The present disclosure relates to 3?3? cyclic phosphonate dinucleotides of general formula (I), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of the substances and other medicaments or pharmaceuticals. The disclosure also relates to compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases.Type: ApplicationFiled: March 4, 2020Publication date: May 12, 2022Applicant: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Gabriel BIRKUS, Ondrej PAV, Petra BREHOVA, Ondrej SIMAK
-
Patent number: 11292812Abstract: The present invention relates to 3?3?-cyclic dinucleotides modified with a 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.Type: GrantFiled: April 4, 2019Date of Patent: April 5, 2022Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Gabriel Birkus, Ondrej Pav, Ivan Rosenberg, Ondrej Simak
-
Patent number: 11203610Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.Type: GrantFiled: December 19, 2018Date of Patent: December 21, 2021Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
-
Patent number: 11149052Abstract: The present disclosure relates to 2?3?-cyclic dinucleotides modified with a 2?- or 3?-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein.Type: GrantFiled: April 4, 2019Date of Patent: October 19, 2021Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Gabriel Birkus, Ondrej Pav, Ivan Rosenberg, Ondrej Simak
-
Patent number: 10966999Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.Type: GrantFiled: December 19, 2018Date of Patent: April 6, 2021Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
-
Patent number: 10294262Abstract: The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.Type: GrantFiled: March 8, 2017Date of Patent: May 21, 2019Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: Aurelie Bourderioux, Michal Hocek, Petr Naus
-
Patent number: 9624257Abstract: The invention provides compounds of formula I: wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.Type: GrantFiled: March 17, 2016Date of Patent: April 18, 2017Assignee: Institute of Organic Chemistry and Biochemistry of the ASCR, V.V.I.Inventors: Aurelie Bourderioux, Michal Hocek, Petr Naus
-
Patent number: 9586986Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.Type: GrantFiled: December 5, 2014Date of Patent: March 7, 2017Assignees: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I., PALACKY UNIVERSITY IN OLOMOUCInventors: Michal Hocek, Petr Naus, Olga Caletkova, Marian Hajduch, Petr Dzubak
-
Publication number: 20160159844Abstract: Compounds of Formula I and a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a mixture of optical isomers thereof, as well as compositions which include such compounds and therapeutic methods that utilize such compounds and/or compositions.Type: ApplicationFiled: December 5, 2014Publication date: June 9, 2016Applicants: Institute of Organic Chemistry and Biochemistry ASCR, v.v.i., Palacky University in OlomoucInventors: Michal HOCEK, Petr NAUS, Olga CALETKOVA, Marian HAJDUCH, Petr DZUBAK
-
Patent number: 9200020Abstract: The invention relates to compounds which are useful as inhibitors of 6-oxopurine phosphoribosyltransferases such as hypoxanthine-guanine-(xanthine) phosphoribosyltransferase (HG(X)PRT).Type: GrantFiled: May 7, 2013Date of Patent: December 1, 2015Assignees: THE UNIVERSITY OF QUEENSLAND, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.Inventors: John De Jersey, Luke William Guddat, Dana Hockova, Dianne Therese Keough
-
Publication number: 20150218201Abstract: The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.Type: ApplicationFiled: April 19, 2010Publication date: August 6, 2015Applicant: Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.Inventors: Aurelie Bourderioux, Michal Hocek, Petr Naus
-
Patent number: 8093226Abstract: The invention provides compounds of formula I: wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.Type: GrantFiled: January 15, 2009Date of Patent: January 10, 2012Assignee: Institute of Organic Chemistry and Biochemistry of the ASCR, V.V.I.Inventors: Michal Hocek, Petr Naus
